Entellus Medical (ENTL) 10-Q 7 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 31, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	ENTL
Entity Registrant Name	ENTELLUS MEDICAL INC
Entity Central Index Key	1,374,128
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		18,725,891

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)		Jun. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents		$ 7,529,000	$ 3,484,000	[1]
Short-term investments		71,826,000	0
Accrued interest income		328,000
Accounts receivable, net		9,348,000	8,746,000	[1]
Inventories		2,429,000	2,439,000	[1]
Prepaid expenses and other current assets		1,339,000	883,000	[1]
Total current assets		92,799,000	15,552,000	[1]
PROPERTY AND EQUIPMENT, NET		2,804,000	1,730,000	[1]
OTHER ASSETS
Debt issuance costs, net		206,000	237,000	[1]
Other non-current assets		19,000	1,717,000	[1]
Total assets		95,828,000	19,236,000	[1]
CURRENT LIABILITIES
Accounts payable		2,273,000	2,414,000	[1]
Current portion of long-term debt		2,534,000
Convertible preferred stock warrant liability	[1]		291,000
Accrued expenses		6,287,000	5,084,000	[1]
Total current liabilities		11,094,000	7,789,000	[1]
LONG-TERM LIABILITIES
Long-term debt, less current portion		17,466,000	20,000,000	[1]
Other non-current liabilities		401,000	247,000	[1]
Total liabilities		$ 28,961,000	$ 28,036,000	[1]
COMMITMENTS AND CONTINGENCIES (See Note M)
CONVERTIBLE PREFERRED STOCK, issuable in series, $0.001 par Value; Authorized shares: none at June 30, 2015 and 44,567 at December 31, 2014 Issued and outstanding shares: none at June 30, 2015 and 44,317 at December 31, 2014	[1]		$ 91,553,556
STOCKHOLDERS' EQUITY (DEFICIT) (see Note I)
Preferred stock, $0.001 par value per share: Authorized shares: 10,000 at June 30, 2015 and none at December 31, 2014 Issued and outstanding shares: none
Common stock, $0.001 par value per share: Authorized shares: 200,000 at June 30, 2015 and 62,276 at December 31, 2014 Issued and outstanding shares: 18,724 and 1,887 at June 30, 2015 and December 31, 2014.		$ 19,000	$ 2,000	[1]
Additional paid-in capital		177,825,000	3,402,000	[1]
Accumulated other comprehensive loss		(3,000)
Accumulated deficit		(110,974,000)	(103,758,000)	[1]
Total stockholders' equity (deficit)		66,867,000	(100,354,000)	[1]
Total liabilities and stockholders' equity (deficit)		$ 95,828,000	$ 19,236,000	[1]
[1]	Amounts derived from the audited financial statements of Entellus Medical, Inc. included in its Annual Report on Form 10-K for the year ended December 31, 2014.

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014	[1]
Statement Of Financial Position [Abstract]
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	0	44,567,071
Convertible preferred stock, shares issued	0	44,317,071
Convertible preferred stock, shares outstanding	0	44,317,071
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	0
Preferred stock, shares Issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	62,276,000
Common stock, shares issued	18,724,000	1,887,000
Common stock, shares outstanding	18,724,000	1,887,000
[1]	Amounts derived from the audited financial statements of Entellus Medical, Inc. included in its Annual Report on Form 10-K for the year ended December 31, 2014.

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenue	$ 15,191	$ 12,498	$ 28,693	$ 22,673
Cost of goods sold	3,348	2,716	6,297	5,014
Gross profit	11,843	9,782	22,396	17,659
Operating expenses
Selling and marketing	9,815	8,163	19,702	15,885
Research and development	1,308	1,047	2,608	2,163
General and administrative	3,074	1,223	5,890	2,381
Total operating expenses	14,197	10,433	28,200	20,429
Loss from operations	(2,354)	(651)	(5,804)	(2,770)
Other income (expense)
Interest income	50	1	71	5
Interest expense	(562)	(523)	(1,481)	(944)
Other non-operating income	(2)		(2)	1
Total other expense, net	(514)	(522)	(1,412)	(938)
Net loss	(2,868)	(1,173)	(7,216)	(3,708)
Other comprehensive loss
Unrealized loss on short term investments, net of tax	(23)		(2)
Foreign currency translation loss, net of tax	(1)		(1)
Comprehensive loss	$ (2,892)	$ (1,173)	$ (7,219)	$ (3,708)
Net loss per share, basic and diluted	$ (0.15)	$ (0.81)	$ (0.46)	$ (2.59)
Weighted average common shares used to compute net loss per share, basic and diluted	18,718	1,455	15,647	1,434

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015		Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (7,216)		$ (3,708)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	414		294
Amortization of debt issuance costs	30		30
Amortization of premium on investments	198
Accretion of final payment fee on long-term debt	154		107
Deferred rent	(2)		(9)
Gain on disposal of equipment			(1)
Stock-based compensation	1,076		95
Changes in fair value of convertible preferred stock warrants	357		98
Changes in operating assets and liabilities:
Accrued interest income	(328)
Accounts receivables, net	(604)		(1,861)
Inventories	10		(540)
Prepaid expenses and other current assets	(456)		(1)
Other non-current assets	1,698
Accounts payable	(141)		696
Accrued expenses	1,206		930
Net cash used in operating activities	(3,604)		(3,870)
Cash flows from investing activities:
Purchase of property and equipment	(1,488)		(538)
Proceeds from sale of property and equipment			1
Purchase of investments	(83,586)
Proceeds from maturities of short-term investments	11,560
Net cash used in investing activities	(73,514)		(537)
Cash Flows from Financing Activities:
Proceeds from stock options exercised	211		75
Proceeds from initial public offering, net of issuance costs	80,953
Repurchase of common stock	(1)
Net cash provided by financing activities	81,163		75
Net increase (decrease) in cash and cash equivalents	4,045		(4,332)
Cash and cash equivalents - beginning of period	3,484	[1]	7,709
Cash and cash equivalents - end of period	7,529		3,377
Supplemental schedule of non-cash investing and financing activities:
Cash paid for interest	$ 924		$ 621
[1]	Amounts derived from the audited financial statements of Entellus Medical, Inc. included in its Annual Report on Form 10-K for the year ended December 31, 2014.

Organization

Organization	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Organization	NOTE A. ORGANIZATION Nature of Business Entellus Medical, Inc. (the “Company”) was incorporated in Delaware and its facilities are located in Plymouth, Minnesota. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (“ENT”) physicians to treat patients with chronic sinusitis by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation performed in the physician office or the operating room. The Company currently sells product through its sales force in the United States and United Kingdom and to a limited number of additional countries through international distributors. The Company operates in one segment.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE B. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Preparation The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The interim financial data as of June 30, 2015, is unaudited and is not necessarily indicative of the results for a full year. In the opinion of the Company’s management, the interim data includes only normal and recurring adjustments necessary for a fair statement of the Company’s financial results for the three and six months ended June 30, 2015 and 2014. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 that has been filed with the SEC. Initial Public Offering In February 2015, the Company completed its initial public offering (“IPO”) by issuing 5,294 shares of common stock, at an offering price of $17.00 per share, for net proceeds of approximately $80,953 after deducting underwriting discounts, commissions and offering expenses payable by the Company. In connection with the IPO, the Company’s outstanding shares of convertible preferred stock were automatically converted into an aggregate of 11,404 shares of common stock, and the Company’s outstanding warrants to purchase shares of convertible preferred stock were automatically converted into warrants to purchase up to an aggregate of 38 shares of common stock, resulting in the reclassification of the related redeemable convertible preferred stock warrant liability of $648 to additional paid-in-capital. 1-for-4 Reverse Stock Split In connection with the IPO, the Company’s board of directors and stockholders approved a reverse stock split of the Company’s common stock on a 1-for-4 basis. The reverse stock split became effective on January 12, 2015. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock converted into common stock immediately prior to the closing of the IPO. Accordingly, all share and per share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split and adjustment of the preferred stock’s conversion ratios. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from those estimates. Significant Accounting Policies Other than the changes described below, there have been no changes in the Company’s significant accounting policies for the three and six months ended June 30, 2015, as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014. Cash and Cash Equivalents Cash equivalents are stated at fair value and include short-term, highly liquid investments with remaining maturities of 90 days or less at the date of purchase. Cash equivalents consist of money market funds recorded at fair value and held-to-maturity corporate debt securities recorded at amortized costs. Short-term and Long-term Investments Short-term and long-term investments represent holdings of marketable securities in accordance with the Company’s investment policy and cash management strategy. Short-term investments are classified as available-for-sale and mature within 12 months from the balance sheet date. Investments with maturity dates greater than one year from the balance sheet date are classified as long-term investments. At the time that the maturity dates of these investments become one year or less, the securities are reclassified to short-term investments. The Company’s investments are recorded at fair value, with any unrealized gains and losses reported as a component of stockholders’ equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The cost of investments sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of interest income or expense. These investments are deemed Level 2 assets under the fair value hierarchy as their fair value is determined under a market approach using valuation models that utilize observable inputs, including maturity date, issue date, settlements date, and current interest rates. Deferred Offering Costs Deferred offering costs were capitalized and consisted primarily of legal, accounting and other direct fees and costs related to the IPO. The deferred offering costs included in other non-current assets were offset against the IPO proceeds upon the closing of the IPO in February 2015. There were no deferred offering costs capitalized as of June 30, 2015. Convertible Preferred Stock Warrant Liability The Company issued warrants to purchase shares of convertible preferred stock in connection with the Company’s entry into its original credit facility in October 2012. The warrants are recorded at fair value using the Black Scholes model. The fair value of these warrants is remeasured at each financial reporting period with any changes in fair value being recognized as a component of other income (expense) in the statements of operations and comprehensive loss. In connection with completion of the IPO, in January 2015, the Company performed the final remeasurement of the warrant liability. There were no costs and costs of $357 for the three and six months ended June 30, 2015, respectively, recorded as interest expense from the final remeasurement. Upon the closing of the IPO, warrants to purchase shares of convertible preferred stock automatically converted into warrants to purchase shares of common stock. The Company reclassified the warrant liability to additional paid-in capital, as the warrants met the definition of an equity instrument. Principles of Consolidation The consolidated financial statements include the accounts of Entellus Medical, Inc., and its wholly owned subsidiary. All significant intercompany transactions and accounts have been eliminated. U.S. GAAP is applied when determining whether an entity is subject to consolidation. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board, (“FASB”) issued Accounting Standards Update, (“ASU”) No. 2014-09, Revenue from Contracts with Customers. This standard will eliminate the transaction and industry specific revenue recognition guidance under current U.S. GAAP and replace it with a principles based approach for determining revenue recognition. The new guidance for private companies is effective for annual and interim periods beginning after December 15, 2017; however, under the Jumpstart Our Business Startups Act, the Company has the ability to defer the adoption to interim periods beginning after December 31, 2017. The Company is in the process of evaluating the impact of the adoption of this standard. In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, (“ASU 2015-02”). The new consolidation standard amended the process that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. ASU 2015-02 is effective for the annual period beginning after December 15, 2015, and for annual and interim periods thereafter. Early application is permitted. The adoption of ASU 2015-02 is not expected to have a material impact on the Company’s financial position or results of operations. In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance (“ASU 2015-03”), which changes the presentation of debt issuance costs in financial statements. Under ASU 2015-03, an entity presents such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs is reported as interest expense. ASU 2015-03 is effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The Company does not believe that adoption of ASU 2015-03 will have a significant impact on the Company’s consolidated financial statements. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory (“ASU 2015-11”), which requires inventory not measured using either the last in, first out or the retail inventory method to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation. The new standard will be effective January 1, 2017 and will be applied prospectively. Early adoption is permitted.

Composition of Certain Financia

Composition of Certain Financial Statement Items	6 Months Ended
	Jun. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Composition of Certain Financial Statement Items	NOTE C. COMPOSITION OF CERTAIN FINANCIAL STATEMENT ITEMS Inventories June 30, December 31, 2015 2014 Finished Goods $ 967 $ 859 Work in process 374 318 Raw materials 1,088 1,262 Total $ 2,429 $ 2,439 Property and Equipment June 30, December 31, 2015 2014 Furniture and office equipment $ 452 $ 401 Computer hardware and software 1,203 837 Laboratory equipment 1,976 1,427 Tooling and molds 1,237 1,237 Leasehold improvements 494 494 $ 5,362 $ 4,396 Less accumulated depreciation and amortization (3,177 ) (2,768 ) Property and equipment in progress 619 102 Total $ 2,804 $ 1,730 Depreciation and amortization expense was $216 and $154 during the three months ended June 30, 2015 and 2014, respectively, and $414 and $294 during the six months ended June 30, 2015 and 2014, respectively. Other Non-Current Assets June 30, December 31, 2015 2014 Security deposit on operating lease $ 19 $ 19 Deferred offering costs — 1,698 Total $ 19 $ 1,717 Accrued Expenses June 30, December 31, 2015 2014 Compensation and commissions payable $ 3,864 $ 3,001 Royalty payable 1,620 1,537 Other accrued expenses 803 546 Total $ 6,287 $ 5,084

Liquidity and Business Risks

Liquidity and Business Risks	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Liquidity and Business Risks	NOTE D. LIQUIDITY AND BUSINESS RISKS As of June 30, 2015, the Company had cash, cash equivalents and short-term investments of $79,355 and an accumulated deficit of $110,974. In February 2015, the Company completed its IPO by issuing 5,294 shares of common stock at an offering price of $17.00 per share, for net proceeds of approximately $80,953, after deducting underwriting discounts and commissions and offering expenses. Prior to the IPO, the Company financed its operations with a combination of revenue, private placements of convertible preferred securities and amounts borrowed under its credit facility. Following the IPO, the Company expects that its cash and cash equivalents, short-term investments, revenue and available debt financing arrangements will be sufficient to fund its operations through at least the next twelve months.

Short-Term and Long-Term Invest

Short-Term and Long-Term Investments	6 Months Ended
	Jun. 30, 2015
Investments Debt And Equity Securities [Abstract]
Short-Term and Long-Term Investments	NOTE E. SHORT-TERM AND LONG-TERM INVESTMENTS The Company determines the appropriate classification of its investments at the time of purchase and revaluates such determinations at each balance sheet date. Marketable securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are recorded as cash equivalents on the balance sheet, based on contractual maturity date and are stated at amortized cost. Investments in marketable securities of $300 were classified as cash equivalents as of June 30, 2015. Marketable securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Marketable securities classified as available-for-sale are carried at fair market value, with the unrealized gains and losses included in the determination of comprehensive income and reported in stockholders’ equity. The following is a summary of the available-for-sale investments by type of instrument (included in short or long-term investments in the condensed consolidated balance sheet) as of June 30, 2015. As of December 31, 2014, there were no short or long-term investments. Unrealized Unrealized Gain in Losses in Accumulated Accumulated Other Other Amortized Comprehensive Comprehensive Estimated June 30, 2015 Cost Income Income Fair Value Short-Term Commercial paper $ 18,741 $ 17 $ — $ 18,758 Corporate bonds 28,112 — (18 ) 28,094 Foreign assets 24,975 — (1 ) 24,974 Total short-term investments 71,828 17 (19 ) 71,826 Total available-for-sale securities $ 71,828 $ 17 $ (19 ) $ 71,826 Based on an evaluation of securities that have been in a loss position, the Company did not recognize any other-than-temporary impairment charges during the three and six months ended June 30, 2015. The Company considered various factors which included a credit and liquidity assessment of the underlying securities and the Company’s intent and ability to hold the underlying securities until the estimated date of recovery of its amortized cost. Contractual maturities of held-to-maturity and available-for-sale securities at June 30, 2015, are as follows: Mature in one year or less $ 71,826 Mature in 1-5 years — Total $ 71,826

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE F. FAIR VALUE MEASUREMENTS As of June 30, 2015 and as of December 31, 2014, the carrying amounts of cash and cash equivalents, receivables, accounts payable and accrued expenses approximated their estimated fair values because of the short term nature of these financial instruments. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three categories: · Level 1: Quoted market prices in active markets for identical assets or liabilities. · Level 2: Includes other than level 1 inputs that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the asset or liabilities. · Level 3: Unobservable inputs that are supported by little or no market activities, which would require the Company to develop its own assumptions. Short and Long-term Investments The following is a summary of available-for-sale investments by type of instrument measured at fair value on a recurring basis at June 30, 2015. As of December 31, 2014, there were no available-for-sale investments. June 30, 2015 Level 1 Level 2 Level 3 Total Commercial paper $ — $ 18,758 $ — $ 18,758 Corporate bonds — 28,094 — 28,094 Foreign assets — 24,974 — 24,974 Total $ — $ 71,826 $ — $ 71,826 There were no transfers in and out of Level 1, Level 2 or Level 3 fair value measurement during the three and six months ended June 30, 2015. Convertible Preferred Stock Warranty Liability The following table sets forth a summary of the changes in the estimated fair value of the Company’s convertible preferred stock warrants, which represents financial instruments that were categorized as Level 3, according to the three-level fair value hierarchy. Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Beginning of the period $ — $ 208 $ 291 $ 211 Issued — — — — Exercised — — — — Expired — — — — Reclassified to equity (1) — — (648 ) — Change in fair value — 101 357 98 End of the period $ — $ 309 $ — $ 309 (1) In connection with the closing of the IPO in February 2015, warrants to purchase shares of convertible preferred stock were converted to warrants to purchase shares of common stock, resulting in the reclassification of the related convertible preferred stock warrant liability to additional paid-in-capital. The fair market value of the convertible preferred stock prior to the IPO was determined using the option pricing method and the probability weighted expected return method. The fair value of the convertible preferred stock warrant liability was determined using the Black-Scholes option pricing model with the following assumptions: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Expected life in years N/A 8.3 7.5 8.3 Risk-free interest rate N/A 2.1 % 1.6 % 2.1 % Expected dividend yield N/A 0.0 % 0.0 % 0.0 % Expected volatility N/A 50 % 56 % 50 %

Debt

Debt	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt	NOTE G. DEBT On May 19, 2015, the Company entered into an amendment to the Company’s amended and restated loan and security agreement (the “credit facility”) with Oxford Finance LLC (the “lender”) changing the Company’s obligations related to foreign subsidiaries. Under the credit facility, the Company can borrow up to a total of $25,000 in three tranches at a fixed rate of 9.40%. The first tranche of $15,000, including the refinance of $7,500 previously outstanding, was borrowed in December 2013. In connection with the funding of the first tranche, the Company paid a prorated final payment fee on the original credit facility of $143. The second tranche of up to $5,000 was available through December 31, 2014, of which $5,000 was borrowed during the three months ended December 31, 2014. The third tranche of up to $5,000 is available at any time through December 31, 2015, subject to the achievement by the Company of certain revenue milestones. The credit facility matures and all amounts borrowed thereunder are due on December 1, 2018. As a result of the $5,000 borrowed in 2014, all amounts borrowed under the credit facility are interest only through January 2016 (24 months), after which the Company will make monthly payments of principal and interest. The interest-only period may be extended to 36 months based on funding and revenue milestones provided for in the agreement. In addition to the principal and interest payments, under the credit facility the Company is required to pay a final payment fee of 7.15% on all amounts outstanding, which is being accrued over the credit facility term and shall be due at the earlier of maturity or prepayment. If the Company repays all of the amounts borrowed under the loan on or prior to maturity, the Company will also be required to pay a prepayment fee equal to 0.75%. As of June 30, 2015 and December 31, 2014, the Company has borrowed and had outstanding $20,000 of debt under the credit facility. As of June 30, 2015 and as of December 31, 2014, the carrying amounts of debt approximates fair market value due to the fixed term nature of the credit facility. The fair value of the Company’s debt is considered a Level 3 measurement.

Convertible Preferred Stock

Convertible Preferred Stock	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Convertible Preferred Stock	NOTE H. CONVERTIBLE PREFERRED STOCK In connection with the IPO in February 2015, the 44,317 shares of convertible preferred stock were converted into 11,404 shares of common stock, resulting in the reclassification of the related redeemable convertible preferred stock of $91,554 to common stock and additional paid-in-capital. A summary of the Company’s convertible preferred stock is as follows (presented in actual amounts): June 30, 2015 December 31, 2014 Number of Number of Number of Number of shares Number of shares shares Shares issued and Carrying Shares issued and converted Carrying authorized outstanding value authorized outstanding common Stock value Series A — — — 2,440,000 2,440,000 610,000 $ 2,963,745 Series B — — — 4,986,188 4,986,188 1,246,547 8,988,134 Series C — — — 3,717,329 3,717,329 1,254,375 14,937,389 Series D — — — 15,310,943 15,310,943 3,827,736 29,822,047 Series E — — — 18,112,611 17,862,611 4,465,653 34,842,241 Total — — — 44,567,071 44,317,071 11,404,311 $ 91,553,556

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stockholders' Equity (Deficit)	NOTE I. STOCKHOLDERS’ EQUITY (DEFICIT) Preferred Stock In connection with the IPO, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation authorizes 10,000 shares of preferred stock. As of June 30, 2015, no preferred stock had been issued. Common Stock In May 2014, the Company amended its certificate of incorporation to increase the authorized number of shares of common stock available for issuance from 57,000 to 57,565 shares of $0.001 par value common stock. In December 2014, the Company further amended its certificate of incorporation to increase the authorized number of common stock shares available for issuance to 62,276. In connection with the IPO, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation authorizes 200,000 shares of common stock. The common stockholders are generally entitled to one vote for each share held on all matters submitted to a vote of the stockholders and do not have any cumulative voting rights. The Company’s common stockholders are entitled to receive proportionally any dividends declared by the Company’s Board of Directors, subject to any preferential dividend rights of outstanding preferred stock. In the event of the Company’s liquidation or dissolution, the common stockholders are entitled to share ratably in all assets remaining after payment of all debts and other liabilities, subject to any preferential rights of any outstanding preferred stock. The common stockholders have no preemptive, subscription, redemption or conversion rights. 2015 Incentive Award Plan In December 2014, the Company’s Board of Directors adopted, and in January 2015 the Company’s stockholders approved, the 2015 Plan. The 2015 Plan became effective in connection with the IPO, at which time the Company ceased making awards under the 2006 Plan. Under the 2015 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and certain other awards to individuals who are employees, officers, directors or consultants of the Company. A total of 1,346 shares of common stock were initially reserved for issuance under the 2015 Plan. In addition, the number of shares available for issuance under the 2015 Plan will be annually increased by an amount equal to the lesser of (A) 875 shares, (B) 4% of the outstanding shares of the Company’s common stock as of the last day of our immediately preceding fiscal year or (C) an amount determined by the Company’s Board of Directors. A summary of the Company’s stock option activity and related information is as follows: Six Months Ended June 30, 2015 Weighted average Aggregate Weighted remaining intrinsic average contractual value Options exercise price term ($000) Outstanding, beginning of period 2,098 $ 7.38 8.8 years $ 8,385 Granted 270 26.37 Exercised (139 ) 1.51 Cancelled — — Forfeited (24 ) 9.18 Outstanding, end of period 2,205 10.05 8.6 years $ 27,548 Exercisable 532 3.06 6.7 years $ 10,066 The aggregate pre-tax intrinsic value of options exercised was $1,876 and $136 for the six months ended June 30, 2015 and 2014, respectively. The aggregate pre-tax intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise or June 30, 2015. The total cash received upon the exercise of options was $211 and $75 during the six months ended June 30, 2015 and 2014, respectively.

Stock Based Compensation Expens

Stock Based Compensation Expense	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation Expense	NOTE J. STOCK-BASED COMPENSATION EXPENSE Stock-based compensation expense is reflected in the Condensed Consolidated Statement of Operations and Comprehensive Loss for the three and six months ended June 30, 2015 and 2014, as follows: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Cost of goods sold $ 12 $ 2 $ 22 $ 5 Selling and marketing 138 23 225 40 Research and development 56 11 100 25 General and administrative 404 12 729 25 Total $ 610 $ 48 $ 1,076 $ 95 The amount of unearned stock-based compensation currently estimated to be expensed through the year 2019 related to unvested employee stock-based payment awards as of June 30, 2015, is approximately $10,048. The weighted average period over which the unearned stock-based compensation is expected to be recognized as of June 30, 2015, is approximately 3.5 years. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to accelerate, increase or cancel any remaining unearned stock-based compensation expense. Future stock-based compensation expense and unearned stock-based compensation will increase to the extent that the Company grants additional share-based payments. The Company estimates the fair value of stock-based compensation on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model determines the fair value of stock-based payment awards based on the fair market value of the Company’s common stock on the date of grant and is affected by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the fair market value of the Company’s common stock, volatility over the expected term of the awards and actual and projected employee stock option exercise behaviors. The Company has opted to use the “simplified method” for estimating the expected term of options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. Due to the Company’s limited operating history and a lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the share-based payments. The Company will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for the Company’s common stock becomes available. The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the Company’s stock options. The expected dividend assumption is based on the Company’s history of not paying dividends and its expectation that it will not declare dividends for the foreseeable future. As stock-based compensation expense recognized in the financial statements is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. Forfeitures are estimated based on estimated future employee turnover and historical experience. The fair value of the options granted to employees or directors during the six months ended June 30, 2015 and 2014, was estimated as of the grant date using the Black-Scholes model assuming the weighted average assumptions listed in the following table: Six Months Ended June 30, 2015 2014 Expected life in years 6.0 6.0 Risk-free interest rate 1.7 % 1.9 % Expected dividend yield 0 % 0 % Expected volatility 56 % 65 % Weighted average fair value $ 13.95 $ 2.08

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	NOTE K. INCOME TAXES We did not record a federal or state income tax benefit for our losses for the three and six months ended June 30, 2015 and 2014 due to our conclusion that full valuation allowance is required against our deferred tax assets.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share	NOTE L. EARNINGS PER SHARE Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Because the Company has reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share for those periods as all potentially dilutive shares consisting of convertible preferred stock, stock options and warrants were antidilutive in those periods. The following table sets forth the computation of the Company’s net loss per share: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Net Loss $ (2,868 ) $ (1,173 ) $ (7,216 ) $ (3,708 ) Weighted average common stock outstanding 18,718 1,455 15,647 1,434 Net loss per share, basic and diluted $ (0.15 ) $ (0.81 ) $ (0.46 ) $ (2.59 ) The following potentially dilutive securities outstanding have been excluded from the computations of diluted earnings per share because such securities have an antidilutive impact due to losses reported: June 30, 2015 2014 Convertible preferred stock outstanding — 11,404 Convertible preferred stock warrants — 38 Common stock warrants 38 — Common stock options 2,205 1,284 Total 2,243 12,726

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE M. COMMITMENTS AND CONTINGENCIES Operating Leases As of June 30, 2015, the Company has two leased facilities under operating lease agreements. The Company entered into a 41-month lease in February 2012, effective April 1, 2012, for its corporate headquarters. The Company entered into a 50-month lease on June 30, 2014, effective July 1, 2014, for additional distribution space in a second facility. On February 26, 2015, the Company exercised its right to extend the lease term of its manufacturing and corporate facility for an additional three years through August 2018. On June 30, 2015, the Company entered into amendments to each lease agreement, among other things, to expand the space occupied by the Company at the property at which the Company’s corporate headquarters are located, and to extend the term of each lease agreement through June 2021, with an option to extend for an additional term through June 2024. Rental payments on operating leases are charged to expense on a straight-line basis over the period of the lease. The lease agreement requires the Company to pay executory costs such as real estate taxes, insurance and repairs, and includes renewal and escalation clauses. Approximate minimum annual future obligations which include monthly contractual lease payments under operating leases with initial terms in excess of one year are as follows: 2015 (remaining) $ 104 2016 351 2017 366 2018 373 2019 381 2020 and thereafter 586 Total $ 2,161 Total lease expense was approximately $84 and $70 for the three months ended June 30, 2015 and 2014, respectively, and $174 and $138 for the six months ended June 30, 2015 and 2014, respectively.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Preparation	Basis of Preparation The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The interim financial data as of June 30, 2015, is unaudited and is not necessarily indicative of the results for a full year. In the opinion of the Company’s management, the interim data includes only normal and recurring adjustments necessary for a fair statement of the Company’s financial results for the three and six months ended June 30, 2015 and 2014. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 that has been filed with the SEC.
Initial Public Offering	Initial Public Offering In February 2015, the Company completed its initial public offering (“IPO”) by issuing 5,294 shares of common stock, at an offering price of $17.00 per share, for net proceeds of approximately $80,953 after deducting underwriting discounts, commissions and offering expenses payable by the Company. In connection with the IPO, the Company’s outstanding shares of convertible preferred stock were automatically converted into an aggregate of 11,404 shares of common stock, and the Company’s outstanding warrants to purchase shares of convertible preferred stock were automatically converted into warrants to purchase up to an aggregate of 38 shares of common stock, resulting in the reclassification of the related redeemable convertible preferred stock warrant liability of $648 to additional paid-in-capital.
Reverse Stock Split	1-for-4 Reverse Stock Split In connection with the IPO, the Company’s board of directors and stockholders approved a reverse stock split of the Company’s common stock on a 1-for-4 basis. The reverse stock split became effective on January 12, 2015. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock converted into common stock immediately prior to the closing of the IPO. Accordingly, all share and per share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split and adjustment of the preferred stock’s conversion ratios.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash equivalents are stated at fair value and include short-term, highly liquid investments with remaining maturities of 90 days or less at the date of purchase. Cash equivalents consist of money market funds recorded at fair value and held-to-maturity corporate debt securities recorded at amortized costs.
Short-term and Long-term Investments	Short-term and Long-term Investments Short-term and long-term investments represent holdings of marketable securities in accordance with the Company’s investment policy and cash management strategy. Short-term investments are classified as available-for-sale and mature within 12 months from the balance sheet date. Investments with maturity dates greater than one year from the balance sheet date are classified as long-term investments. At the time that the maturity dates of these investments become one year or less, the securities are reclassified to short-term investments. The Company’s investments are recorded at fair value, with any unrealized gains and losses reported as a component of stockholders’ equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The cost of investments sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of interest income or expense. These investments are deemed Level 2 assets under the fair value hierarchy as their fair value is determined under a market approach using valuation models that utilize observable inputs, including maturity date, issue date, settlements date, and current interest rates.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs were capitalized and consisted primarily of legal, accounting and other direct fees and costs related to the IPO. The deferred offering costs included in other non-current assets were offset against the IPO proceeds upon the closing of the IPO in February 2015. There were no deferred offering costs capitalized as of June 30, 2015.
Convertible Preferred Stock Warrant Liability	Convertible Preferred Stock Warrant Liability The Company issued warrants to purchase shares of convertible preferred stock in connection with the Company’s entry into its original credit facility in October 2012. The warrants are recorded at fair value using the Black Scholes model. The fair value of these warrants is remeasured at each financial reporting period with any changes in fair value being recognized as a component of other income (expense) in the statements of operations and comprehensive loss. In connection with completion of the IPO, in January 2015, the Company performed the final remeasurement of the warrant liability. There were no costs and costs of $357 for the three and six months ended June 30, 2015, respectively, recorded as interest expense from the final remeasurement. Upon the closing of the IPO, warrants to purchase shares of convertible preferred stock automatically converted into warrants to purchase shares of common stock. The Company reclassified the warrant liability to additional paid-in capital, as the warrants met the definition of an equity instrument.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Entellus Medical, Inc., and its wholly owned subsidiary. All significant intercompany transactions and accounts have been eliminated. U.S. GAAP is applied when determining whether an entity is subject to consolidation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board, (“FASB”) issued Accounting Standards Update, (“ASU”) No. 2014-09, Revenue from Contracts with Customers. This standard will eliminate the transaction and industry specific revenue recognition guidance under current U.S. GAAP and replace it with a principles based approach for determining revenue recognition. The new guidance for private companies is effective for annual and interim periods beginning after December 15, 2017; however, under the Jumpstart Our Business Startups Act, the Company has the ability to defer the adoption to interim periods beginning after December 31, 2017. The Company is in the process of evaluating the impact of the adoption of this standard. In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, (“ASU 2015-02”). The new consolidation standard amended the process that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. ASU 2015-02 is effective for the annual period beginning after December 15, 2015, and for annual and interim periods thereafter. Early application is permitted. The adoption of ASU 2015-02 is not expected to have a material impact on the Company’s financial position or results of operations. In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance (“ASU 2015-03”), which changes the presentation of debt issuance costs in financial statements. Under ASU 2015-03, an entity presents such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs is reported as interest expense. ASU 2015-03 is effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The Company does not believe that adoption of ASU 2015-03 will have a significant impact on the Company’s consolidated financial statements. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory (“ASU 2015-11”), which requires inventory not measured using either the last in, first out or the retail inventory method to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation. The new standard will be effective January 1, 2017 and will be applied prospectively. Early adoption is permitted.

Composition of Certain Financ20

Composition of Certain Financial Statement Items (Tables)	6 Months Ended
	Jun. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Inventories	Inventories June 30, December 31, 2015 2014 Finished Goods $ 967 $ 859 Work in process 374 318 Raw materials 1,088 1,262 Total $ 2,429 $ 2,439
Schedule of Property and Equipment	Property and Equipment June 30, December 31, 2015 2014 Furniture and office equipment $ 452 $ 401 Computer hardware and software 1,203 837 Laboratory equipment 1,976 1,427 Tooling and molds 1,237 1,237 Leasehold improvements 494 494 $ 5,362 $ 4,396 Less accumulated depreciation and amortization (3,177 ) (2,768 ) Property and equipment in progress 619 102 Total $ 2,804 $ 1,730
Schedule of Other Non-Current Assets	Other Non-Current Assets June 30, December 31, 2015 2014 Security deposit on operating lease $ 19 $ 19 Deferred offering costs — 1,698 Total $ 19 $ 1,717
Schedule of Accrued Expenses	Accrued Expenses June 30, December 31, 2015 2014 Compensation and commissions payable $ 3,864 $ 3,001 Royalty payable 1,620 1,537 Other accrued expenses 803 546 Total $ 6,287 $ 5,084

Short-Term and Long-Term Inve21

Short-Term and Long-Term Investments (Tables)	6 Months Ended
	Jun. 30, 2015
Investments Debt And Equity Securities [Abstract]
Summary of Investments by Type of Instrument	The following is a summary of the available-for-sale investments by type of instrument (included in short or long-term investments in the condensed consolidated balance sheet) as of June 30, 2015. As of December 31, 2014, there were no short or long-term investments. Unrealized Unrealized Gain in Losses in Accumulated Accumulated Other Other Amortized Comprehensive Comprehensive Estimated June 30, 2015 Cost Income Income Fair Value Short-Term Commercial paper $ 18,741 $ 17 $ — $ 18,758 Corporate bonds 28,112 — (18 ) 28,094 Foreign assets 24,975 — (1 ) 24,974 Total short-term investments 71,828 17 (19 ) 71,826 Total available-for-sale securities $ 71,828 $ 17 $ (19 ) $ 71,826
Summary of Contractual Maturities of Held-to-Maturity and Available-for-Sale Securities	Contractual maturities of held-to-maturity and available-for-sale securities at June 30, 2015, are as follows: Mature in one year or less $ 71,826 Mature in 1-5 years — Total $ 71,826

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Summary of Available for Sale Investments at Fair Value on Recurring Basis	The following is a summary of available-for-sale investments by type of instrument measured at fair value on a recurring basis at June 30, 2015. As of December 31, 2014, there were no available-for-sale investments. June 30, 2015 Level 1 Level 2 Level 3 Total Commercial paper $ — $ 18,758 $ — $ 18,758 Corporate bonds — 28,094 — 28,094 Foreign assets — 24,974 — 24,974 Total $ — $ 71,826 $ — $ 71,826
Summary of Changes in Estimated Fair Value of Company's Convertible Preferred Stock Warrants	The following table sets forth a summary of the changes in the estimated fair value of the Company’s convertible preferred stock warrants, which represents financial instruments that were categorized as Level 3, according to the three-level fair value hierarchy. Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Beginning of the period $ — $ 208 $ 291 $ 211 Issued — — — — Exercised — — — — Expired — — — — Reclassified to equity (1) — — (648 ) — Change in fair value — 101 357 98 End of the period $ — $ 309 $ — $ 309 (1) In connection with the closing of the IPO in February 2015, warrants to purchase shares of convertible preferred stock were converted to warrants to purchase shares of common stock, resulting in the reclassification of the related convertible preferred stock warrant liability to additional paid-in-capital.
Summary of Fair Value of Convertible Preferred Stock Warrant Liability	The fair market value of the convertible preferred stock prior to the IPO was determined using the option pricing method and the probability weighted expected return method. The fair value of the convertible preferred stock warrant liability was determined using the Black-Scholes option pricing model with the following assumptions: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Expected life in years N/A 8.3 7.5 8.3 Risk-free interest rate N/A 2.1 % 1.6 % 2.1 % Expected dividend yield N/A 0.0 % 0.0 % 0.0 % Expected volatility N/A 50 % 56 % 50 %

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Summary of Convertible Preferred Stock	A summary of the Company’s convertible preferred stock is as follows (presented in actual amounts): June 30, 2015 December 31, 2014 Number of Number of Number of Number of shares Number of shares shares Shares issued and Carrying Shares issued and converted Carrying authorized outstanding value authorized outstanding common Stock value Series A — — — 2,440,000 2,440,000 610,000 $ 2,963,745 Series B — — — 4,986,188 4,986,188 1,246,547 8,988,134 Series C — — — 3,717,329 3,717,329 1,254,375 14,937,389 Series D — — — 15,310,943 15,310,943 3,827,736 29,822,047 Series E — — — 18,112,611 17,862,611 4,465,653 34,842,241 Total — — — 44,567,071 44,317,071 11,404,311 $ 91,553,556

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity and Related Information	A summary of the Company’s stock option activity and related information is as follows: Six Months Ended June 30, 2015 Weighted average Aggregate Weighted remaining intrinsic average contractual value Options exercise price term ($000) Outstanding, beginning of period 2,098 $ 7.38 8.8 years $ 8,385 Granted 270 26.37 Exercised (139 ) 1.51 Cancelled — — Forfeited (24 ) 9.18 Outstanding, end of period 2,205 10.05 8.6 years $ 27,548 Exercisable 532 3.06 6.7 years $ 10,066

Stock Based Compensation Expe25

Stock Based Compensation Expense (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock-based Compensation Expense in Condensed Statement of Operations and Comprehensive Loss	Stock-based compensation expense is reflected in the Condensed Consolidated Statement of Operations and Comprehensive Loss for the three and six months ended June 30, 2015 and 2014, as follows: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Cost of goods sold $ 12 $ 2 $ 22 $ 5 Selling and marketing 138 23 225 40 Research and development 56 11 100 25 General and administrative 404 12 729 25 Total $ 610 $ 48 $ 1,076 $ 95
Summary of Weighted Average Assumptions Used in Black-Scholes Model in Estimating Fair Value of Option Granted	The fair value of the options granted to employees or directors during the six months ended June 30, 2015 and 2014, was estimated as of the grant date using the Black-Scholes model assuming the weighted average assumptions listed in the following table: Six Months Ended June 30, 2015 2014 Expected life in years 6.0 6.0 Risk-free interest rate 1.7 % 1.9 % Expected dividend yield 0 % 0 % Expected volatility 56 % 65 % Weighted average fair value $ 13.95 $ 2.08

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share	The following table sets forth the computation of the Company’s net loss per share: Three Months Ended Six Months Ended June 30, June 30, 2015 2014 2015 2014 Net Loss $ (2,868 ) $ (1,173 ) $ (7,216 ) $ (3,708 ) Weighted average common stock outstanding 18,718 1,455 15,647 1,434 Net loss per share, basic and diluted $ (0.15 ) $ (0.81 ) $ (0.46 ) $ (2.59 )
Schedule of Antidilutive Securities Outstanding Excluded from Computation of Earnings Per Share	The following potentially dilutive securities outstanding have been excluded from the computations of diluted earnings per share because such securities have an antidilutive impact due to losses reported: June 30, 2015 2014 Convertible preferred stock outstanding — 11,404 Convertible preferred stock warrants — 38 Common stock warrants 38 — Common stock options 2,205 1,284 Total 2,243 12,726

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Summary of Annual Future Minimum Lease Payments	Approximate minimum annual future obligations which include monthly contractual lease payments under operating leases with initial terms in excess of one year are as follows: 2015 (remaining) $ 104 2016 351 2017 366 2018 373 2019 381 2020 and thereafter 586 Total $ 2,161

Organization - Additional Infor

Organization - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2015Segment
Organization And Nature Of Business Textual [Abstract]
Number of operating segment	1

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Additional Information (Detail)	Jan. 12, 2015	Feb. 28, 2015USD ($)$ / sharesshares	Jun. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2014shares
Accounting Policies [Line Items]
Number of common stock converted from preferred stock | shares						11,404,311
Reverse stock split conversion ratio	0.25
Changes in fair value of convertible preferred stock warrants				$ 357,000	$ 98,000
Interest Expense [Member]
Accounting Policies [Line Items]
Changes in fair value of convertible preferred stock warrants			$ 0	357,000
Other Non-current Assets [Member]
Accounting Policies [Line Items]
Deferred offering costs capitalized			$ 0	$ 0
Initial Public Offering [Member]
Accounting Policies [Line Items]
Common stock, shares issued | shares		5,294,000
Common stock offering price per share | $ / shares		$ 17
Proceeds from issuance of common stock, net of issuance costs		$ 80,953,000
Number of common stock converted from preferred stock | shares		11,404,000
Shares purchasable upon conversion of preferred stock | shares		38,000
Preferred stock warrant liability reclassified		$ 648,000

Composition of Certain Financ30

Composition of Certain Financial Statement Items - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Finished Goods	$ 967	$ 859
Work in process	374	318
Raw materials	1,088	1,262
Total	$ 2,429	$ 2,439	[1]
[1]	Amounts derived from the audited financial statements of Entellus Medical, Inc. included in its Annual Report on Form 10-K for the year ended December 31, 2014.

Composition of Certain Financ31

Composition of Certain Financial Statement Items - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property plant and equipment, Gross	$ 5,362	$ 4,396
Less accumulated depreciation and amortization	(3,177)	(2,768)
Property and equipment in progress	619	102
Total	2,804	1,730	[1]
Furniture and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, Gross	452	401
Computer Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, Gross	1,203	837
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, Gross	1,976	1,427
Tooling and Molds [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, Gross	1,237	1,237
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, Gross	$ 494	$ 494
[1]	Amounts derived from the audited financial statements of Entellus Medical, Inc. included in its Annual Report on Form 10-K for the year ended December 31, 2014.

Composition of Certain Financ32

Composition of Certain Financial Statement Items - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Property Plant And Equipment [Abstract]
Depreciation and amortization	$ 216	$ 154	$ 414	$ 294

Composition of Certain Financ33

Composition of Certain Financial Statement Items - Schedule of Other Non-Current Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Assets Noncurrent [Abstract]
Security deposit on operating lease	$ 19	$ 19
Deferred offering costs		1,698
Other non-current assets, Total	$ 19	$ 1,717	[1]
[1]	Amounts derived from the audited financial statements of Entellus Medical, Inc. included in its Annual Report on Form 10-K for the year ended December 31, 2014.

Composition of Certain Financ34

Composition of Certain Financial Statement Items - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Payables And Accruals [Abstract]
Compensation and commissions payable	$ 3,864	$ 3,001
Royalty payable	1,620	1,537
Other accrued expenses	803	546
Accrued expenses, Total	$ 6,287	$ 5,084	[1]
[1]	Amounts derived from the audited financial statements of Entellus Medical, Inc. included in its Annual Report on Form 10-K for the year ended December 31, 2014.

Liquidity and Business Risks -

Liquidity and Business Risks - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended
	Feb. 28, 2015	Jun. 30, 2015	Dec. 31, 2014	[1]
Subsidiary, Sale of Stock [Line Items]
Cash, cash equivalents and short-term investments		$ 79,355
Accumulated deficit		$ 110,974	$ 103,758
Initial Public Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, shares issued	5,294
Common stock offering price per share	$ 17
Proceeds from issuance of common stock, net of issuance costs	$ 80,953
[1]	Amounts derived from the audited financial statements of Entellus Medical, Inc. included in its Annual Report on Form 10-K for the year ended December 31, 2014.

Short-term and Long-term Inve36

Short-term and Long-term Investments - Additional Information (Detail) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Short-term investments	$ 71,826,000	$ 71,826,000	$ 0
Long-term investments			$ 0
Other-than-temporary impairment charges	0	0
Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Investment in marketable securities	$ 300	$ 300

Short-term and Long-term Inve37

Short-term and Long-term Investments - Summary of Investments by Type of Instrument (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 71,828,000
Unrealized Gain in Accumulated Other Comprehensive Income	17,000
Unrealized Losses in Accumulated Other Comprehensive Income	(19,000)
Estimated Fair Value	71,826,000	$ 0
Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	71,828,000
Unrealized Gain in Accumulated Other Comprehensive Income	17,000
Unrealized Losses in Accumulated Other Comprehensive Income	(19,000)
Estimated Fair Value	71,826,000
Short-term Investments [Member] | Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	28,112,000
Unrealized Losses in Accumulated Other Comprehensive Income	(18,000)
Estimated Fair Value	28,094,000
Short-term Investments [Member] | Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	18,741,000
Unrealized Gain in Accumulated Other Comprehensive Income	17,000
Estimated Fair Value	18,758,000
Short-term Investments [Member] | Foreign Assets [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	24,975,000
Unrealized Losses in Accumulated Other Comprehensive Income	(1,000)
Estimated Fair Value	$ 24,974,000

Short-term and Long-term Inve38

Short-term and Long-term Investments - Summary of Contractual Maturities of Held-to-Maturity and Available-for-Sale Securities (Detail) $ in Thousands	Jun. 30, 2015USD ($)
Investments Debt And Equity Securities [Abstract]
Mature in one year or less	$ 71,826
Total	$ 71,826

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Available-for-sale investments	$ 71,826,000	$ 71,826,000	$ 0
Transfer of assets between level 1, level 2 or level 3	$ 0	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Available for Sale Investments at Fair Value on Recurring Basis (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments	$ 71,826,000	$ 0
Fair Value, Measurements, Recurring [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments	71,826,000
Fair Value, Measurements, Recurring [Member] | Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments	28,094,000
Fair Value, Measurements, Recurring [Member] | Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments	18,758,000
Fair Value, Measurements, Recurring [Member] | Foreign Assets [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments	$ 24,974,000
Fair Value, Measurements, Recurring [Member] | Level 1 [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Foreign Assets [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments
Fair Value, Measurements, Recurring [Member] | Level 2 [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments	$ 71,826,000
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments	28,094,000
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments	18,758,000
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Foreign Assets [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments	$ 24,974,000
Fair Value, Measurements, Recurring [Member] | Level 3 [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments
Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments
Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments
Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Foreign Assets [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale investments

Fair Value Measurements - Sum41

Fair Value Measurements - Summary of Changes in Estimated Fair Value of Company's Convertible Preferred Stock Warrants (Detail) - Convertible Preferred Stock Warrants [Member] - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Class of Warrant or Right [Line Items]
Beginning of the period	$ 208	$ 291	$ 211
Reclassified to equity		(648)
Change in fair value	101	$ 357	98
End of the period	$ 309		$ 309

Fair Value Measurements - Sum42

Fair Value Measurements - Summary of Fair Value of Convertible Preferred Stock Warrant Liability (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]
Expected life in years		8 years 3 months 18 days	7 years 6 months	8 years 3 months 18 days
Risk-free interest rate		2.10%	1.60%	2.10%
Expected dividend yield		0.00%	0.00%	0.00%
Expected volatility		50.00%	56.00%	50.00%

Debt - Additional Information (

Debt - Additional Information (Detail) - Credit Facility [Member]	May. 19, 2015USD ($)Tranches	Dec. 31, 2013USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2014USD ($)
Debt Instrument [Line Items]
Line of credit facility, amount outstanding			$ 20,000,000	$ 20,000,000
Fixed interest floor rate	9.40%
Number of tranches | Tranches	3
Maturity date of debt instrument			Dec. 1, 2018
Credit facility interest payment period			24 months
Credit facility interest payment expected extension period			36 months
Credit facility final payment fee			7.15%
Credit facility prepayment fee			0.75%
First Tranche [Member]
Debt Instrument [Line Items]
Line of credit facility, amount outstanding		$ 15,000,000
Payment fee		143,000
Second Tranche [Member]
Debt Instrument [Line Items]
Line of credit facility, amount outstanding				5,000,000
Third Tranche [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 5,000,000
Scenario, Previously Reported [Member] | First Tranche [Member]
Debt Instrument [Line Items]
Line of credit facility, amount outstanding		$ 7,500,000
Maximum [Member]
Debt Instrument [Line Items]
Line of credit facility, amount outstanding	$ 25,000,000
Maximum [Member] | Second Tranche [Member]
Debt Instrument [Line Items]
Line of credit facility, amount outstanding				$ 5,000,000

Convertible Preferred Stock - A

Convertible Preferred Stock - Additional Information (Detail) - USD ($)	1 Months Ended	6 Months Ended	12 Months Ended
	Feb. 28, 2015	Jun. 30, 2015	Dec. 31, 2014
Temporary Equity [Line Items]
Preferred stock, conversion basis		In connection with the IPO in February 2015, the 44,317 shares of convertible preferred stock were converted into 11,404 shares of common stock, resulting in the reclassification of the related redeemable convertible preferred stock of $91,554 to common stock and additional paid-in-capital.
Number of preferred stock converted to common stock	44,317,000
Number of common stock converted from preferred stock			11,404,311
Convertible preferred stock			$ 91,553,556
Convertible Preferred Stock Outstanding [Member]
Temporary Equity [Line Items]
Convertible preferred stock	$ 91,554,000
Initial Public Offering [Member]
Temporary Equity [Line Items]
Number of common stock converted from preferred stock	11,404,000

Convertible Preferred Stock - S

Convertible Preferred Stock - Summary of Convertible Preferred Stock (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014		Jun. 30, 2015
Temporary Equity [Line Items]
Number of shares authorized	44,567,071	[1]	0
Number of shares issued	44,317,071	[1]	0
Number of shares outstanding	44,317,071	[1]	0
Number of shares converted to common Stock	11,404,311
Carrying Value	$ 91,553,556
Series A [Member]
Temporary Equity [Line Items]
Number of shares authorized	2,440,000
Number of shares issued	2,440,000
Number of shares outstanding	2,440,000
Number of shares converted to common Stock	610,000
Carrying Value	$ 2,963,745
Series B [Member]
Temporary Equity [Line Items]
Number of shares authorized	4,986,188
Number of shares issued	4,986,188
Number of shares outstanding	4,986,188
Number of shares converted to common Stock	1,246,547
Carrying Value	$ 8,988,134
Series C [Member]
Temporary Equity [Line Items]
Number of shares authorized	3,717,329
Number of shares issued	3,717,329
Number of shares outstanding	3,717,329
Number of shares converted to common Stock	1,254,375
Carrying Value	$ 14,937,389
Series D [Member]
Temporary Equity [Line Items]
Number of shares authorized	15,310,943
Number of shares issued	15,310,943
Number of shares outstanding	15,310,943
Number of shares converted to common Stock	3,827,736
Carrying Value	$ 29,822,047
Series E [Member]
Temporary Equity [Line Items]
Number of shares authorized	18,112,611
Number of shares issued	17,862,611
Number of shares outstanding	17,862,611
Number of shares converted to common Stock	4,465,653
Carrying Value	$ 34,842,241
[1]	Amounts derived from the audited financial statements of Entellus Medical, Inc. included in its Annual Report on Form 10-K for the year ended December 31, 2014.

Stockholders' Equity (Deficit46

Stockholders' Equity (Deficit) - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Jan. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014		May. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares authorized		10,000,000		0	[1]
Preferred stock, shares Issued		0		0	[1]
Common stock, shares authorized		200,000,000		62,276,000	[1]		57,000,000
Common stock, par value		$ 0.001		$ 0.001	[1]
2015 Incentive Award Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance	1,346,000
Annual percentage increase in shares available for grant	4.00%
Annual increase in shares available for grant	875,000
Total cash received upon the exercise of options		$ 211	$ 75
Aggregate pre-tax intrinsic value of options exercised		$ 1,876	$ 136
After Amendment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized				62,276,000		57,565,000
[1]	Amounts derived from the audited financial statements of Entellus Medical, Inc. included in its Annual Report on Form 10-K for the year ended December 31, 2014.

Stockholders' Equity (Deficit47

Stockholders' Equity (Deficit) - Summary of Stock Option Activity and Related Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options outstanding, Beginning balance	2,098
Options Granted	270
Options Exercised	(139)
Options Forfeited	(24)
Options outstanding, Ending balance	2,205	2,098
Options Exercisable, Ending balance	532
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price, Beginning balance	$ 7.38
Weighted Average Exercise Price, Granted	26.37
Weighted Average Exercise Price, Exercised	1.51
Weighted Average Exercise Price, Forfeited	9.18
Weighted Average Exercise Price, Ending balance	10.05	$ 7.38
Weighted Average Exercise Price, Exercisable	$ 3.06
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	8 years 7 months 6 days	8 years 9 months 18 days
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	8 years 7 months 6 days	8 years 9 months 18 days
Weighted Average Remaining Contractual Term, Exercisable, Ending balance	6 years 8 months 12 days
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value [Roll Forward]
Aggregate Intrinsic Value, Beginning balance	$ 8,385
Aggregate Intrinsic Value, Ending balance	27,548	$ 8,385
Aggregate Intrinsic Value Exercisable Ending balance	$ 10,066

Stock Based Compensation Expe48

Stock Based Compensation Expense - Summary of Stock-Based Compensation Expense in Condensed Statement of Operations and Comprehensive Loss (Detail) - Employee Stock Option [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 610	$ 48	$ 1,076	$ 95
Cost of Goods Sold [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	12	2	22	5
Selling and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	138	23	225	40
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	56	11	100	25
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 404	$ 12	$ 729	$ 25

Stock Based Compensation Expe49

Stock Based Compensation Expense - Additional Information (Detail) - Jun. 30, 2015 - USD ($) $ in Thousands	Total
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested employee stock-based payment award	$ 10,048
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period for unearned stock-based compensation cost	3 years 6 months

Stock Based Compensation Expe50

Stock Based Compensation Expense - Summary of Weighted Average Assumptions Used in Black-Scholes Model in Estimating Fair Value of Option Granted (Detail) - Employee Stock Option [Member] - $ / shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	6 years	6 years
Risk-free interest rate	1.70%	1.90%
Expected dividend yield	0.00%	0.00%
Expected volatility	56.00%	65.00%
Weighted average fair value	$ 13.95	$ 2.08

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Federal income tax benefit	$ 0	$ 0	$ 0	$ 0
State income tax benefit	$ 0	$ 0	$ 0	$ 0

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share [Abstract]
Net loss	$ (2,868)	$ (1,173)	$ (7,216)	$ (3,708)
Weighted average common stock outstanding	18,718	1,455	15,647	1,434
Net loss per share, basic and diluted	$ (0.15)	$ (0.81)	$ (0.46)	$ (2.59)

Earnings Per Share - Schedule53

Earnings Per Share - Schedule of Antidilutive Securities Outstanding Excluded from Computation of Earnings Per Share (Detail) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive potential common shares excluded from computation of diluted earning per share	2,243	12,726
Convertible Preferred Stock Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive potential common shares excluded from computation of diluted earning per share		11,404
Convertible Preferred Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive potential common shares excluded from computation of diluted earning per share		38
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive potential common shares excluded from computation of diluted earning per share	38
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive potential common shares excluded from computation of diluted earning per share	2,205	1,284

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	Feb. 26, 2015	Jun. 30, 2014	Feb. 29, 2012	Jun. 30, 2015USD ($)Facilities	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)Facilities	Jun. 30, 2014USD ($)
Operating Leased Assets [Line Items]
Number of leased facilities under operating lease agreement | Facilities				2		2
Operating leased facility, period		50 months	41 months
Operating leased facility, effective date		Jul. 1, 2014	Apr. 1, 2012
Operating leased facility, additional period	3 years
Operating leased facility, amendment description						On June 30, 2015, the Company entered into amendments to each lease agreement, among other things, to expand the space occupied by the Company at the property at which the Company’s corporate headquarters are located, and to extend the term of each lease agreement through June 2021, with an option to extend for an additional term through June 2024.
Total lease expense				$ 84	$ 70	$ 174	$ 138
Amendment Facility Lease Agreement [Member]
Operating Leased Assets [Line Items]
Operating leased facility, effective date						Feb. 1, 2016

Commitment and Contingencies -

Commitment and Contingencies - Summary of Annual Future Minimum Lease Payments (Detail) $ in Thousands	Jun. 30, 2015USD ($)
Commitments And Contingencies Disclosure [Abstract]
2015 (remaining)	$ 104
2,016	351
2,017	366
2,018	373
2,019	381
2020 and thereafter	586
Total minimum payment required	$ 2,161